CLRB

We rate Cellectar Biosciences, Inc. (CLRB) as Avoid with a composite score of 35.6/100 at a current price of $3.31. The stock falls in the bottom quintile of our universe across key quantitative factors, and the multi-factor weakness suggests a high probability of continued underperformance.

The rating is primarily driven by strength in momentum (64th percentile) and investment (19th percentile), which together account for the majority of the composite score. Offsetting weakness in value (5th percentile) and stability (12th percentile) tempers our overall conviction. We assign a No Moat rating (15/100), Very High uncertainty, and Poor capital allocation.

Key items to watch: valuation compression risk if growth disappoints. Any material change in these dynamics could warrant a reassessment of our rating. The moat trend is stable, which suggests the competitive landscape is stable for now.

Cellectar Biosciences, Inc. holds a top-quartile position (#0 of 50) within the Manufacturing sector, based on our composite quantitative scoring across quality, value, momentum, and stability factors. The composite score of 35.6/100 places it at rank #4049 in our full 7,333-stock universe. At $18M in market capitalization, Cellectar Biosciences, Inc. is a small-cap player in the Manufacturing space, which limits certain scale advantages but may allow for more agile strategic execution.

Momentum indicators (64th percentile) are constructive regarding the near-term price trend. Revenue growth data is unavailable, limiting our ability to confirm whether momentum is fundamentally supported.

Margin data is not available for Cellectar Biosciences, Inc., which limits our assessment of the company's cost structure and operating efficiency. We rely on factor-based signals to infer business quality in the absence of detailed margin data.

At a current price of $3.31, Cellectar Biosciences, Inc. is trading at a premium to fundamental value. Our value factor score of 5/100 reflects a composite assessment across multiple valuation metrics including price-to-earnings, price-to-book, EV/EBITDA, and price-to-sales ratios relative to both sector peers and the broader market. The premium valuation implies the market is pricing in significant future growth or quality improvements that are not yet fully reflected in current fundamentals.

The stock currently trades at P/B of 1.8x. We evaluate these multiples in the context of both absolute levels and sector-relative positioning to form our valuation view.

We assign a Very High uncertainty rating to Cellectar Biosciences, Inc.. The stock exhibits multiple compounding risk factors: elevated market sensitivity (beta of 9.90), below-average price stability (12th percentile), weak quality scores (18th percentile). The extreme uncertainty around future cash flows makes precise valuation difficult, and the range of outcomes is exceptionally wide. Only investors with high risk tolerance and extended time horizons should consider this name.

Specific risk factors that inform our assessment include: elevated market sensitivity (beta of 9.90); below-average price stability (12th percentile); weak quality scores (18th percentile). Each of these factors independently widens the distribution of potential outcomes, and in combination they create a risk profile that demands careful position sizing. The stability factor at the 12th percentile and quality factor at the 18th percentile provide a quantitative summary of the overall risk landscape.

We identify limited risk mitigants at this time, which contributes to our very high uncertainty assessment. Investors should monitor for improvement in balance sheet metrics, margin stability, and business predictability that could warrant a downgrade in our risk assessment over time.

We rate Cellectar Biosciences, Inc.'s capital allocation as Poor. Key concerns include low returns on equity (-389.6%), weak asset returns (ROA -213.0%). Exemplary capital allocators generate ROE above 20% and maintain conservative leverage — Cellectar Biosciences, Inc. significantly underperforms these benchmarks, raising questions about management's ability to create shareholder value.

Investors should scrutinize management's reinvestment decisions and balance sheet trajectory before committing capital. Poor capital allocation often compounds over time: overlevered balance sheets limit strategic flexibility, while low returns on capital destroy shareholder value. We would need to see sustained improvement in profitability metrics and balance sheet discipline before considering an upgrade.

In summary, Cellectar Biosciences, Inc. receives a Avoid rating with a composite score of 35.6/100 (rank #4049 of 7,333). Our quantitative framework assigns a No Moat (15/100, trend: stable), Very High uncertainty, and Poor capital allocation. The average factor score across quality, value, momentum, stability, and investment is 24/100.

Our analysis does not support a constructive view on Cellectar Biosciences, Inc. at this time. The combination of limited competitive advantages, very high uncertainty, and poor capital allocation suggests unfavorable risk-reward at current levels. We recommend investors avoid new positions and existing holders consider reducing exposure.